哪个是心血管安全的顶级参与者? 在CLL中,ibrutinib与obinutuzumab对比
Annamaria Mascolo1,2, Raffaella Di Napoli1,2, Nunzia Balzano1,2
1Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, Napoli, Italy.
这项研究发现,在慢性淋巴细胞白血病 (CLL) 患者中,与obinutuzumab相比,ibrutinib的心血管事件报告频率更高. 需要进一步的研究才能充分理解ibrutinib.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心脏病学 心脏病学
- 在瘤学瘤学.
背景情况:
- 易布鲁替尼是布鲁顿的氨酸激酶 (BTK) 抑制剂,用于慢性淋巴细胞白血病 (CLL).
- 了解ibrutinib的心脏安全概况对于患者管理至关重要.
- 与obinutuzumab等其他治疗方法进行比较是必要的,以评估相对风险.
研究的目的:
- 为了比较ibrutinib与obinutuzumab的心脏安全概况.
- 分析与这些治疗相关的心血管事件报告频率.
主要方法:
- 使用欧洲药物监督数据库 (Eudravigilance) 进行回顾性药物监督研究.
- 从2014年1月1日到2022年9月30日期间收集的数据.
- 报告心血管事件发生频率的比较,用于ibrutinib,obinutuzumab和它们的组合.
主要成果:
- 分析了2,291例心血管 (CV) 病例;1,965例与ibrutinib相关.
- 与obinutuzumab (ROR 3.22) 相比,ibrutinib的CV事件报告频率更高.
- 心房动和出血是最常见的CV事件.
结论:
- 与obinutuzumab相比,易布鲁丁尼显示出较高的心血管事件报告频率.
- 这些发现强调了需要在接受ibrutinib治疗的患者中进行仔细的心脏监测的必要性.
- 需要进一步的研究来阐明与ibrutinib相关的特定心脏风险.
更多相关视频
09:02Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Cardiovascular Drugs: Classification based on Therapeutic Indications
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
